Literature DB >> 9287965

Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans.

H B el-Serag1, A Sonnenberg.   

Abstract

BACKGROUND & AIMS: It has been speculated that gastroesophageal reflux disease (GERD) represents a risk factor for the occurrence of extraesophageal complications. The aim of this study was to compare the comorbid occurrence of sinus, laryngeal, and pulmonary diseases in case subjects with and control subjects without reflux esophagitis.
METHODS: The case population consisted of all patients with erosive esophagitis (International Classification of Diseases code 530.1) or esophageal stricture (ICD code 530.3) who were discharged from hospitals of the Department of Veteran Affairs between 1981 and 1994. In multivariate logistic regressions, the occurrence of sinus, pharyngeal, laryngeal, or pulmonary disease was compared between cases with and an equal number of controls without esophagitis or stricture.
RESULTS: A total of 101,366 case subjects was analyzed. Erosive esophagitis and esophageal stricture were associated with sinusitis (odds ratio, 1.60; 95% confidence interval, 1.51-1.70), pharyngitis (1.48; 1.15-1.89), aphonia (1.81; 1.18-2.80), laryngitis (2.01; 1.53-2.63), laryngeal stenosis (2.02; 1.12-3.65), chronic bronchitis (1.28; 1.22-1.34), asthma (1.51; 1.43-1.59), chronic obstructive pulmonary disease (1.22; 1.16-1.27), pulmonary fibrosis (1.36; 1.25-1.48), bronchiectasis (1.26; 1.09-1.47), pulmonary collapse (1.31; 1.23-1.40), and pneumonia (1.15; 1.12-1.18).
CONCLUSIONS: Patients with reflux esophagitis are at an increased risk of harboring a large variety of sinus, pharyngeal, laryngeal, and pulmonary diseases.

Entities:  

Mesh:

Year:  1997        PMID: 9287965     DOI: 10.1016/s0016-5085(97)70168-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  65 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 2.  Gastroesophageal reflux and altered motility in lung transplant rejection.

Authors:  J M Castor; R K Wood; A J Muir; S M Palmer; R A Shimpi
Journal:  Neurogastroenterol Motil       Date:  2010-05-26       Impact factor: 3.598

3.  Laparoscopic antireflux surgery at an outpatient surgery center.

Authors:  C R Finley; J B McKernan
Journal:  Surg Endosc       Date:  2001-05-11       Impact factor: 4.584

Review 4.  Epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  J Dent; H B El-Serag; M-A Wallander; S Johansson
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 5.  Gastro-oesophageal reflux disease.

Authors:  Mark Fox; Ian Forgacs
Journal:  BMJ       Date:  2006-01-14

6.  [Clinical and experimental considerations for evaluation of Eustachian tube physiology].

Authors:  H Sudhoff; T Ockermann; R Mikolajczyk; J Ebmeyer; D Korbmacher; D Garten; S Schreiber
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

Review 7.  Gastroesophageal reflux/laryngopharyngeal reflux disease: a critical analysis of the literature.

Authors:  M N Kotby; O Hassan; Aly M N El-Makhzangy; M Farahat; P Milad
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

8.  Insight Into the Relationship Between Gastroesophageal Reflux Disease and Asthma.

Authors:  Fehmi Ates; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

Review 9.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 10.  The pulmonary side of reflux disease: from heartburn to lung fibrosis.

Authors:  Marco E Allaix; P Marco Fisichella; Imre Noth; Bernardino M Mendez; Marco G Patti
Journal:  J Gastrointest Surg       Date:  2013-04-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.